Jim Cramer likes these dividend stocks for 2025. All three dividend stocks are solid financially and pay good yields.

AbbVie's Q2 results show Skyrizi and Rinvoq powering growth, offsetting Humira declines and lifting 2025 sales outlook.

Spoiler: You would have done well -- and even better if you'd reinvested your dividends.

The "it" factor. Some stocks have it.

What does it take to be a Dividend Champion? A company must increase its dividend for at least 25 consecutive years for its stock to make the list.

On Thursday, AbbVie Inc. ABBV reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion.

Reports Second-Quarter Diluted EPS of $0.52 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.97, an Increase of 12.1 Percent; These Results Include an Unfavorable Impact of $...

Investors seeking defensive companies that pay substantial dividends are drawn to the Dividend Aristocrats, and with good reason.

Often, great investing boils down to holding on to great stocks. It can be as simple as that.

ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.

I like dividend stocks. You probably should, too, even if you aren't interested in the income they provide.

I maintain my Buy rating on AbbVie, emphasizing its medium-to-long-term potential despite recent outlook downgrades and tariff risks. Recent guidance cuts are minor and don't meaningfully undermine...

AbbVie Inc. (ABBV) has emerged as a strong performer in financial and technical terms, attracting investor attention due to its long-term growth potential. With consistent revenue generation and ex...

Dividend investing, like most things in life, can be rewarding if done correctly or a headache if you make crucial mistakes. The key to dividend investing is to pick the right types of dividend sto...

Shares of Glenmark Pharmaceuticals jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie for its cancer treatment.